Cancer biotech Onconova Therapeutics sets terms for $60 million IPO

By
A A A

Onconova Therapeutics, a biotech focused on developing novel small molecule drug candidates for cancer treatment, announced terms for its IPO on Thursday. The Newtown, PA-based company plans to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Onconova Therapeutics would command a fully diluted market value of $261 million.

Onconova Therapeutics, which was founded in 1998 and booked $47 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol ONTX. Onconova Therapeutics initially filed confidentially on May 3, 2013. Citi and Leerink Swann are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ONTX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com